-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3362 The 3D- Telomere Profiling Assay Identifies High Risk Smoldering Multiple Myeloma Patients with High Precision

Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
artificial intelligence (AI), assays, Diseases, emerging technologies, Biological Processes, molecular biology, Technology and Procedures, machine learning, molecular testing, omics technologies, Pathology
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Sherif Louis, PhD1*, Sabine Mai2* and Hans Knecht, MD3

1Telo Genomics Corp., Toronto, ON, Canada
2University of Manitoba, Winnipeg, MB, CAN
3Hôpital Général Juif - Sir Mortimer B. Davis, Montréal, QC, CAN

Smoldering multiple myeloma (SMM) is an asymptomatic precursor stage of multiple myeloma (MM). According to the international Myeloma Working Group data (Blood Cancer J. 2020 Oct 16;10(10):102) the probability of progression to MM is 22% at 2 years, and 42% and 64% at 5 and 10 years, respectively. Thus, identification of patients with high risk of early progression to MM is crucial for optimal treatment management.

Genomic instability is a sensitive indicator of disease progression in cancer. Telomere dysfunction is an early event in genomic instability. The 3-dimensional (3D) spatial profiling of telomeres using TeloView technology allows for quantification of telomere dysfunction and was shown to be instrumental in risk stratification of cancer patients generally, but particularly in selected hematological malignancies. Importantly, the utility of the 3D-telomere profiling was recently demonstrated in 2 clinical studies validating the utility of 3D telomere profiling as a structural biomarker to identify high risk SMM patients. The two studies achieved accuracy of >80% and specificity and sensitivity of over 80% & 76% respectively in a training dataset study followed by a blind validation (Kumar S.et al 2023. J Clin Oncol).

To present the 3D telomere profiling assay as a reliable prognostic tool in the clinic, capable to precisely identify high risk SMM patients, it is important to demonstrate the repeatability and accuracy of the assay. In this study, we conducted a retrospective analytical validation including samples of 20 SMM patients with known progression outcome. The samples of each patient were blindly processed in triplets using the 3D-telomere assay, followed by the TeloView analysis. To eliminate any validation-bias the validation was conducted with uncontrolled variables. Samples were processed blindly by different operators on different dates using different instrumentation.

We interrogated the repeatability and precision of the results of each patient analyzed on 2 levels. First, we calculated coefficient of variation (CV) of telomere predictors of each patient across the three runs; and secondly, we interrogated the repeatability of patient outcome using the scoring model developed and validated in (Kumar et al. 2023, J Clin Oncol) across the three runs of each patient.

We set the acceptable concordance to 80% for CVs (CV <20%) and the acceptable repeatability of patient-outcome as predicted by the scoring model to 80% of the patients included in the study. We report CVs across all the telomere predictors, across the 3 runs of all patients ranging between 2.3 – 17.8. Furthermore, patient outcome as high/low risk of progression was consistent in 17 out of the 20 patients in all 3 runs (85%).

The results of this study demonstrate the 3D-telomere profiling as an accurate and prognostic structural biomarker. The assay shows high level of precision, repeatability, and reliability, and presents a viable solution to accurately identify high risk SMM patients. This will potentially allow the treating physicians to make confident treatment decisions for high risk SMM patients based on the results of the 3D Telomere profiling assay.

Disclosures: Louis: Telo Genomics: Current Employment, Current equity holder in publicly-traded company. Mai: Telo Genomics: Current equity holder in publicly-traded company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties. Knecht: Telo Genomics: Current equity holder in publicly-traded company.

*signifies non-member of ASH